Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Broadcom
AVGO
|
+$2.06B |
| 2 |
Nasdaq
NDAQ
|
+$1.76B |
| 3 |
Wells Fargo
WFC
|
+$1.1B |
| 4 |
Gilead Sciences
GILD
|
+$978M |
| 5 |
Edwards Lifesciences
EW
|
+$964M |
Top Sells
| 1 |
EOG Resources
EOG
|
+$1.82B |
| 2 |
Apple
AAPL
|
+$1.75B |
| 3 |
HCA Healthcare
HCA
|
+$1.51B |
| 4 |
SPDR S&P 500 ETF Trust
SPY
|
+$1.48B |
| 5 |
PNC Financial Services
PNC
|
+$1.29B |
Sector Composition
| 1 | Technology | 23.24% |
| 2 | Healthcare | 19.6% |
| 3 | Financials | 13.95% |
| 4 | Consumer Discretionary | 9.41% |
| 5 | Industrials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1551
KalVista Pharmaceuticals
KALV
$786M
| $1.37M | ﹤0.01% |
117,923
+33,900
| +40% | +$393K |
|
|
AGR
1552
DELISTED
Avangrid, Inc.
AGR
| $1.36M | ﹤0.01% |
38,129
+2,110
| +6% | +$75.5K |
|
|
INZY
1553
DELISTED
Inozyme Pharma
INZY
| $1.36M | ﹤0.01% |
260,719
+27,739
| +12% | +$145K |
|
1554
Protagonist Therapeutics
PTGX
$3.63B
| $1.35M | ﹤0.01% |
+30,079
| New | +$1.35M |
|
1555
Xeris Biopharma Holdings
XERS
$1.24B
| $1.34M | ﹤0.01% |
471,644
+49,535
| +12% | +$141K |
|
1556
Voyager Therapeutics
VYGR
$222M
| $1.34M | ﹤0.01% |
229,369
-17,623
| -7% | -$103K |
|
1557
IDEAYA Biosciences
IDYA
$2.17B
| $1.33M | ﹤0.01% |
42,111
-145,895
| -78% | -$4.62M |
|
1558
Absci
ABSI
$380M
| $1.33M | ﹤0.01% |
348,854
+107,980
| +45% | +$412K |
|
1559
Agios Pharmaceuticals
AGIO
$2.1B
| $1.31M | ﹤0.01% |
29,448
-6,971
| -19% | -$310K |
|
1560
Restaurant Brands International
QSR
$20.3B
| $1.3M | ﹤0.01% |
17,965
+9,496
| +112% | +$686K |
|
1561
Zebra Technologies
ZBRA
$15.9B
| $1.28M | ﹤0.01% |
3,457
+183
| +6% | +$67.8K |
|
1562
SPDR S&P International Small Cap ETF
GWX
$782M
| $1.26M | ﹤0.01% |
37,007
+5,354
| +17% | +$183K |
|
1563
Atour Lifestyle Holdings
ATAT
$5.52B
| $1.25M | ﹤0.01% |
+48,228
| New | +$1.25M |
|
1564
Vanguard Small-Cap Value ETF
VBR
$31.5B
| $1.24M | ﹤0.01% |
6,197
| – | – |
|
1565
Aecom
ACM
$16.5B
| $1.24M | ﹤0.01% |
11,999
+546
| +5% | +$56.4K |
|
|
TSVT
1566
DELISTED
2seventy bio
TSVT
| $1.24M | ﹤0.01% |
262,040
+21,673
| +9% | +$102K |
|
1567
Iovance Biotherapeutics
IOVA
$858M
| $1.22M | ﹤0.01% |
129,482
+12,064
| +10% | +$113K |
|
1568
Altimmune
ALT
$334M
| $1.21M | ﹤0.01% |
197,232
+42,553
| +28% | +$261K |
|
1569
Pan American Silver
PAAS
$14.9B
| $1.21M | ﹤0.01% |
57,677
+26,960
| +88% | +$564K |
|
1570
Arrowhead Research
ARWR
$3.83B
| $1.2M | ﹤0.01% |
61,904
+886
| +1% | +$17.2K |
|
1571
Kiniksa Pharmaceuticals
KNSA
$2.73B
| $1.19M | ﹤0.01% |
+47,717
| New | +$1.19M |
|
1572
Catalyst Pharmaceutical
CPRX
$2.45B
| $1.18M | ﹤0.01% |
+59,584
| New | +$1.18M |
|
1573
J.M. Smucker
SJM
$11.8B
| $1.18M | ﹤0.01% |
9,769
+920
| +10% | +$111K |
|
1574
Albemarle
ALB
$8.54B
| $1.18M | ﹤0.01% |
+12,422
| New | +$1.18M |
|
1575
Mersana Therapeutics
MRSN
$38.2M
| $1.17M | ﹤0.01% |
24,732
+3,417
| +16% | +$161K |
|